NEOGENOMICS INC (NEO)
NEOGENOMICS INC (NEO) from its SEC filings: 2025 revenue $727.3 million (+10% vs the year before), net margin -15%, free cash flow -$21.8 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Services-Testing Laboratories |
| Revenue (2025) | $727.3 million |
| Revenue growth | +10% |
| Net income | -$108.0 million |
| Net margin | -14.8% |
| Free cash flow | -$21.8 million |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +11% |
| Cash | $145.5 million |
| Long-term debt | $374.2 million |
| Share count, 1 year | -0% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.